中华胃肠外科杂志
中華胃腸外科雜誌
중화위장외과잡지
CHINESE JOURNAL OF GASTROINTESTINAL SURGERY
2012年
9期
943-946
,共4页
朱成楚%陈保富%孔敏%王春国%王征%马德华%叶敏华%叶中瑞
硃成楚%陳保富%孔敏%王春國%王徵%馬德華%葉敏華%葉中瑞
주성초%진보부%공민%왕춘국%왕정%마덕화%협민화%협중서
食管肿瘤%术前放化疗%胸腔镜%腹腔镜%食管切除术
食管腫瘤%術前放化療%胸腔鏡%腹腔鏡%食管切除術
식관종류%술전방화료%흉강경%복강경%식관절제술
Esophageal neoplasms%Neoadjuvant chemoradiotherapy%Thoracoscopy%Laparoscopy%Esophagectomy
目的 评估术前放化疗加胸腹腔镜联合手术治疗局部中晚期食管癌的可行性及近期疗效.方法 2011年6月至2012年2月间浙江省台州医院共对1 1例局部中晚期(ⅡB~ⅢA期)食管癌患者予以术前放化疗加胸腹腔镜联合手术.术前化疗采取NP方案(长春瑞滨加顺铂)或TP方案(紫杉醇加顺铂)静脉注射;同期采用常规分割放疗,放疗剂量40 Gy/20 d.放化疗后4~6周施行胸腹腔镜联合经右胸、上腹、左颈三切口食管癌切除术.结果 11例患者均完成预定同步放疗方案,期间9例出现不同程度的骨髓抑制.放化疗结束至手术的时间为(49.6±15.4)d.术中除1例患者(放化疗后75 d手术)局部纤维化形成外,其余10例患者手术难度并未增加;与同期15例行单纯腔镜食管切除术的患者相比,手术时间明显缩短[ (242.3±27.0) min比(280.5±27.2) min,P=0.002],术中出血量明显减少[(168.2±95.6) ml比(244.5±84.8) ml,P=0.042],淋巴结清扫数量相当[(19.5±5.8)枚/例比(20.5±7.1)枚/例,P=0.683],但术后住院时间延长[(18.9±10.3)d比(12.5±4.6)d,P=0.020].术后病理示,4例瘤体明显缩小,7例达到病理完全缓解.术后并发症发生率36.4%(4/11),其中颈部吻合口瘘并肺部感染1例、颈部吻合口瘘并声嘶l例、肺部感染并胸腔积液2例.术后随访1~9个月,未见肿瘤复发.结论 术前放化疗加胸腹腔镜联合手术治疗局部中晚期食管癌安全、可行,近期疗效确切.
目的 評估術前放化療加胸腹腔鏡聯閤手術治療跼部中晚期食管癌的可行性及近期療效.方法 2011年6月至2012年2月間浙江省檯州醫院共對1 1例跼部中晚期(ⅡB~ⅢA期)食管癌患者予以術前放化療加胸腹腔鏡聯閤手術.術前化療採取NP方案(長春瑞濱加順鉑)或TP方案(紫杉醇加順鉑)靜脈註射;同期採用常規分割放療,放療劑量40 Gy/20 d.放化療後4~6週施行胸腹腔鏡聯閤經右胸、上腹、左頸三切口食管癌切除術.結果 11例患者均完成預定同步放療方案,期間9例齣現不同程度的骨髓抑製.放化療結束至手術的時間為(49.6±15.4)d.術中除1例患者(放化療後75 d手術)跼部纖維化形成外,其餘10例患者手術難度併未增加;與同期15例行單純腔鏡食管切除術的患者相比,手術時間明顯縮短[ (242.3±27.0) min比(280.5±27.2) min,P=0.002],術中齣血量明顯減少[(168.2±95.6) ml比(244.5±84.8) ml,P=0.042],淋巴結清掃數量相噹[(19.5±5.8)枚/例比(20.5±7.1)枚/例,P=0.683],但術後住院時間延長[(18.9±10.3)d比(12.5±4.6)d,P=0.020].術後病理示,4例瘤體明顯縮小,7例達到病理完全緩解.術後併髮癥髮生率36.4%(4/11),其中頸部吻閤口瘺併肺部感染1例、頸部吻閤口瘺併聲嘶l例、肺部感染併胸腔積液2例.術後隨訪1~9箇月,未見腫瘤複髮.結論 術前放化療加胸腹腔鏡聯閤手術治療跼部中晚期食管癌安全、可行,近期療效確切.
목적 평고술전방화료가흉복강경연합수술치료국부중만기식관암적가행성급근기료효.방법 2011년6월지2012년2월간절강성태주의원공대1 1례국부중만기(ⅡB~ⅢA기)식관암환자여이술전방화료가흉복강경연합수술.술전화료채취NP방안(장춘서빈가순박)혹TP방안(자삼순가순박)정맥주사;동기채용상규분할방료,방료제량40 Gy/20 d.방화료후4~6주시행흉복강경연합경우흉、상복、좌경삼절구식관암절제술.결과 11례환자균완성예정동보방료방안,기간9례출현불동정도적골수억제.방화료결속지수술적시간위(49.6±15.4)d.술중제1례환자(방화료후75 d수술)국부섬유화형성외,기여10례환자수술난도병미증가;여동기15례행단순강경식관절제술적환자상비,수술시간명현축단[ (242.3±27.0) min비(280.5±27.2) min,P=0.002],술중출혈량명현감소[(168.2±95.6) ml비(244.5±84.8) ml,P=0.042],림파결청소수량상당[(19.5±5.8)매/례비(20.5±7.1)매/례,P=0.683],단술후주원시간연장[(18.9±10.3)d비(12.5±4.6)d,P=0.020].술후병리시,4례류체명현축소,7례체도병리완전완해.술후병발증발생솔36.4%(4/11),기중경부문합구루병폐부감염1례、경부문합구루병성시l례、폐부감염병흉강적액2례.술후수방1~9개월,미견종류복발.결론 술전방화료가흉복강경연합수술치료국부중만기식관암안전、가행,근기료효학절.
Objective To investigate the feasibility and efficacy of neoadjuvant chemoradiotherapy followed by combined thoracoscopic and laparoscopic esophagectomy (CTLE) in the treatment of advanced esophageal carcinoma.Methods From June 2011 to February 2012,11 patients with locally advanced esophageal carcinoma underwent neoadjuvant chemoradiotherapy followed by CTLE (clinical stage Ⅱ B-ⅢA).NP (vinorelbine pin and cisplatin) or TP (programpaclitaxel-pin and cisplatin) were applied as preoperative chemotherapy.During the same period,conventional fractionated radiotherapy was used with the radiation dose of 40 Gy/20 F.At four to six weeks after CRT,11 patients received three-incision CTLE.Results During chemoradiation,9 patients developed bone marrow suppression.The interval between completion of chemoradiation and surgery was (49.6±15.4) d.Intraoperative findings revealed local fibrosis in one patient (75 days after chemoradiation) while operative difficulty was not increased in the remaining 10 patients.Compared to 15 patients who received surgery alone,operative time was shorter[ (242.3±27.0) min vs.(280.5±27.2) min,P=0.002]and intraoperative blood loss was less[(168.2±95.6) ml vs.(244.5±84.8) ml,P=0.042],the number of removal lymph nodes was similar [ (19.5±5.8) vs.(20.5±7.1),P=0.683 ],postoperative hospital stay was prolonged ](18.9±10.3) d vs.(12.5±4.6) d,P=0.020].The postoperative complication rate was 36.4% including cervical anastomotic leak with pulmonary infection (n=l),cervical anastomotic fistula and hoarseness (n=l),pulmonary infection with pleural effusion (n=2).Follow up ranged from 1 to 9 months,and no recurrence was found.Conclusion The neoadjuvant chemoradiotherapy followed by combined thoracoscopic and laparoscopic esophagectomy in the treatment of locally advanced esophageal carcinoma is safe,feasible,and the short-term outcomes are favorable.